|
業務類別
|
Biotechnology |
|
業務概覽
|
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel. |
| 公司地址
| Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002 |
| 電話號碼
| +972 25327151 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.enterabio.com |
| 員工數量
| 22 |
| Ms. Miranda Jayne Toledano |
Director and Chief Executive Officer |
美元 490.00K |
03/06/2026 |
| Dr. Hillel Galitzer, PhD |
Chief Operating Officer |
美元 282.00K |
03/06/2026 |
| Ms. Dana Yaacov-Garbeli |
Chief Financial Officer and Principal Accounting Officer |
-- |
03/06/2026 |
| Dr. Gregory Burshtein, PhD |
Chief of Research and Development |
美元 217.00K |
03/06/2026 |
|
|
| Mr. Geno J. Germano |
Chairman of the Board |
09/02/2026 |
| Mr. Steven D. Rubin |
Independent Director |
04/02/2026 |
| Ms. Miranda Jayne Toledano |
Director and Chief Executive Officer |
03/06/2026 |
| Mr. Yonatan Malca |
Independent Director |
06/10/2026 |
| Ms. Laura J. Hamill |
Independent Director |
06/10/2026 |
| Mr. Sean Ellis |
Independent Director |
03/06/2026 |
| Ms. Haya Taitel |
Independent Director |
28/07/2026 |
|
|
|
|